Mavoglurant
| CAS No. | 543906-09-8 | Cat. No. | BCP20624 |
| Name | Mavoglurant | ||
| Synonyms | AFQ056; AFQ-056; AFQ 056; | ||
| Formula | C19H23NO3 | M. Wt | 313.39 |
| Description | Mavoglurant, aslo known as AFQ056, is an experimental drug candidate for the treatment of fragile X syndrome. Mavoglurant exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results. Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder. | ||
| Pathways | Neuro Signaling Pathway GPCR/G Protein | ||
| Targets | mGluR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.